Cardiology

A secondary analysis of the data collected by the DASH-Sodium trial indicates that dieting and sodium intake limits are additive in their effects on ASCVD risk.

Orchestra BioMed’s Breakthrough Device designation could apply to nearly 8 million patients with uncontrolled hypertension and increased cardiovascular risk

The model could allow cardiologists to inform and prepare patients before symptoms of hypertrophic cardiomyopathy make themselves known.

Christie M. Ballantyne, MD, discusses the role of plozasiran in managing elevated triglycerides and reducing pancreatitis risk.

The scalability and portability of these ECGs could also allow for a community-based approach to heart healthcare.

Anita Radhakrishnan, MD, leads a community screening effort to detect early heart disease in underserved populations in Pittsburgh.

Our top 5 headlines spotlight FDA approvals for maralixibat and dupilumab, plus key trial results in diabetes, cardiovascular disease, and retinal vein occlusion.

Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.

Label updates simplify twice-yearly echo monitoring for eligible patients in the maintenance phase and expand eligibility with reduced contraindications.

Radhakrishnan describes a unique initiative in Pittsburgh promoting health equity and closing the gap in cardiovascular health disparities.

This episode spotlights a pair of studies examining use of semaglutide from the American College of Cardiology's 2025 Scientific Sessions.

Justin Riley Lam, MD, discussed findings from a retrospective cohort analysis at the 2025 ACP Internal Medicine Meeting.

Individuals treated with ezetimibe shortly after myocardial infarction experience an improved prognosis versus those who receive delayed treatment or none at all.

Bristol Myers Squibb says mavacamten missed dual primary endpoints in Phase 3 ODYSSEY-HCM trial for symptomatic non-obstructive HCM.

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

A single infusion of VERVE-102 gene editing therapy achieved dose-dependent lowering in blood PCSK9 and LDL-C in initial results from the Heart-2 trial.

Payal Kohli, MD, explores how evolving tools and strategies in lipid management are reshaping preventive cardiology.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

VERVE-102 is targeting the reduction of LDL-C levels among individuals with hyperlipidemia and high lifetime cardiovascular risk.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Deepak Bhatt, MD, MPH, MBA, explores high-impact trials from ACC.25, including REVERSE-IT, Alpaca, ADVANCE-HTN, SOUL, STRIDE, and DapaTAVI.

AHN is proud to offer three highly skilled chronic total occlusion operators at Allegheny General Hospital.

Complex PAD may be treated by minimally invasive percutaneous transmural arterial bypass (PTAB) using the DETOUR System by Endologix.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

Patients hospitalized for STEMI achieved similar outcomes with rivaroxaban as warfarin after three months of follow-up in the RIVAWAR trial.